NOVOZYMES A/S SPONS.ADR 1 (NZM) — Capital Reinvestment Ratio
NOVOZYMES A/S SPONS.ADR 1 (NZM) has a Capital Reinvestment Ratio of 0.56x as of March 2026, meaning it reinvests 1% of its operating cash flow (€167.10 Million) in capital expenditures (€93.10 Million). Check NOVOZYMES A/S SPONS.ADR 1 (NZM) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
NOVOZYMES A/S SPONS.ADR 1 Capital Reinvestment Ratio (2021–2025)
This chart tracks NOVOZYMES A/S SPONS.ADR 1's Capital Reinvestment Ratio across 5 annual periods. For the full cash flow conversion analysis, see NZM operating cash flow.
Annual Capital Reinvestment Ratio for NOVOZYMES A/S SPONS.ADR 1 (2021–2025)
Year-by-year Capital Reinvestment Ratio for NOVOZYMES A/S SPONS.ADR 1 from 2021 to 2025. See NZM FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.39x | €1.22 Billion | €470.80 Million | ▲ +9.3% |
| 2024 | 0.35x | €1.02 Billion | €359.80 Million | ▼ -28.7% |
| 2023 | 0.50x | €557.10 Million | €275.80 Million | ▼ -31.4% |
| 2022 | 0.72x | €537.65 Million | €387.87 Million | ▲ +136.3% |
| 2021 | 0.31x | €546.17 Million | €166.73 Million | — |